Clinical trials
Phase 1 Scleroderma, Diffuse trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 4 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Terminated | 7 |
| Recruiting | 6 |
| Not yet recruiting | 4 |
| Active, not recruiting | 2 |
| Withdrawn | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boston University | 2 |
| Bristol-Myers Squibb | 2 |
| MedImmune LLC | 2 |
| AbelZeta Inc. | 1 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 1 |
| Allogene Therapeutics | 1 |
| Amgen | 1 |
| Brigham and Women's Hospital | 1 |
| CRISPR Therapeutics | 1 |
| Century Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Scleroderma, Diffuse | 32 |
| Scleroderma, Systemic | 15 |
| Lupus Erythematosus, Systemic | 10 |
| Autoimmune Diseases | 8 |
| Myositis | 8 |
| Lupus Nephritis | 7 |
| Dermatomyositis | 5 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 3 |
| Arthritis, Rheumatoid | 3 |
| Sjogren's Syndrome | 3 |
Trials
Showing 26 to 32 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.